G'day Mega
You are right on both fronts in your last post.
Cancer is an insidious disease that evades detection and mutates to survive. There are many great immunotherapy focused biotechs fighting the good fight with curative intent and if I had the funds would support them all.
From an investment/return perspective my personal favourites listed ASX (after more than a decade) IMM and IMU.
Efti is the most advanced drug in late stage trials and very hopeful of a licensing or outright purchase within next 12 months.
What is concerning, If the latter we have only 761 in the pipeline and disappointingly remains pre clinical stage.
Media, page-382
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.005(1.69%) |
Mkt cap ! $435.7M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.5¢ | 29.5¢ | $598.4K | 2.003M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 192353 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 126073 | 7 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |